Clinical Trial Update: Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS [Phase 1]

View source ↗

Summary

Phase I clinical trial update from Arcellx evaluating cell therapies for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Snippet

Sponsor: Arcellx, Inc. | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: UNKNOWN